Latest Psoriasis Stories
TORONTO, July 15, 2014 /CNW/ - The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now
An investigational medication shows promise in treating the most common skin disorder, often referred to as eczema or atopic dermatitis.
- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints
DUBLIN, July 9, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/3pfrzt/frontier_pharma)
Psoriasis Foundation will drive efforts to cure psoriatic disease, help those affected PORTLAND, Ore., July 9, 2014 /PRNewswire-USNewswire/ -- National Psoriasis Foundation will double the
Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.
Women with long-term high blood pressure (hypertension) appear to be at an increased risk for the skin condition psoriasis, and long-term use of beta (β)-blocker medication to treat hypertension may also increase the risk of psoriasis.
- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union BRUSSELS and REDWOOD CITY, Calif., July 3, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.